Meta‐analysis of sentinel lymph node positivity in thin melanoma (≤1 mm)

Despite the lack of an established survival benefit of sentinel lymph node (SLN) biopsy, this technique has been increasingly applied in the staging of thin (≤1 mm) melanoma patients, without clear evidence to support this recommendation. The authors performed a meta‐analysis to estimate the risk, potential predictors, and outcome of SLN positivity in this group of patients.

[1]  W. Gillanders,et al.  Melanoma thickness and histology predict sentinel lymph node status. , 2001, American journal of surgery.

[2]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Coit,et al.  Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma , 2006, Annals of Surgical Oncology.

[4]  A. Testori,et al.  Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience , 2000, Annals of Surgical Oncology.

[5]  P. Queirolo,et al.  Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review , 2004, Journal of surgical oncology.

[6]  David Elder,et al.  Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. J. Coleman,et al.  The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma , 2006, Annals of Surgical Oncology.

[8]  L. Brogelli,et al.  The prognostic significance of histologic regression in cutaneous melanoma , 1992, Melanoma research.

[9]  N. Cascinelli,et al.  Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. McCready,et al.  Sentinel lymph node biopsy for cutaneous melanoma of the head and neck. , 2005, Annals of surgical oncology.

[11]  C. Garbe,et al.  The New American Joint Committee on Cancer staging system for cutaneous melanoma , 2002, Cancer.

[12]  V. Sondak,et al.  Sentinel node biopsy for thin melanomas: which patients should be considered? , 2005, Cancer control : journal of the Moffitt Cancer Center.

[13]  William G. Cochran,et al.  Experimental designs, 2nd ed. , 1957 .

[14]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[15]  Jeffrey E. Lee,et al.  Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients , 2003, Annals of Surgical Oncology.

[16]  R. Cecchi,et al.  Sentinel lymph node biopsy in patients with thin melanomas , 2007, The Journal of dermatology.

[17]  Jeremy MG Taylor,et al.  Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model , 2004, Annals of Surgical Oncology.

[18]  P. V. van Diest,et al.  No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm , 2001, Melanoma research.

[19]  P. G. Lang,et al.  Sentinel-Node Biopsy or Nodal Observation in Melanoma , 2007 .

[20]  K. Busam,et al.  Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy , 2007, Annals of Surgical Oncology.

[21]  L. Cornelius,et al.  Sentinel lymph node biopsy in patients with thin melanoma. , 2003, Archives of dermatology.

[22]  Jeffrey F Stephens,et al.  Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. , 2003, American journal of surgery.

[23]  B. Balda,et al.  Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: A follow‐up study of 148 patients , 2007, International journal of cancer.

[24]  P. Davidson,et al.  Thin malignant melanomas (< 1.5 mm) with metastasis: a histological study and survival analysis , 1990 .

[25]  P. G. Lang,et al.  Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival , 2007 .

[26]  A. Baron.  Experimental Designs , 1990, The Behavior analyst.

[27]  G. Wilson,et al.  Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[28]  C. Shea,et al.  Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. , 2002, Archives of dermatology.

[29]  M. Mihm,et al.  Histologic regression in malignant melanoma: an interobserver concordance study , 1993, Journal of cutaneous pathology.

[30]  D. Tyler,et al.  Thin Melanomas: Predictive Lethal Characteristics From a 30-Year Clinical Experience , 2003, Annals of surgery.

[31]  L. Talve,et al.  Sentinel node metastasectomy in thin ≤1-mm melanoma , 2005, Langenbeck's Archives of Surgery.

[32]  L. Ferreira,et al.  Vertical growth phase and positive sentinel node in thin melanoma. , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  J. Malvehy,et al.  Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients , 2004, Melanoma research.

[34]  T. Hensing,et al.  Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness ≤1.0 mm) , 2004, Annals of Surgical Oncology.

[35]  P. Davidson,et al.  Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. , 1990, Histopathology.

[36]  M. Lens,et al.  Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy , 2002, The British journal of surgery.

[37]  A. Dobozy,et al.  Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas , 2003, The British journal of dermatology.

[38]  A. Lowy,et al.  Sentinel lymph node biopsy in thin melanoma patients , 2006, Journal of surgical oncology.

[39]  P. Manson,et al.  Sentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary? , 2003, Annals of plastic surgery.

[40]  A. Alavi,et al.  Mitotic Rate as a Predictor of Sentinel Lymph NodePositivity in Patients With Thin Melanomas , 2004, Annals of Surgical Oncology.

[41]  D. Morton,et al.  Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. McCarthy,et al.  Prognosis for patients with thin cutaneous melanoma , 2003, Cancer.

[44]  I. Jacobs,et al.  Role of Sentinel Lymph Node Biopsy in Patients With Thin (<1 mm) Primary Melanoma , 2003, Annals of Surgical Oncology.

[45]  R. Cheney,et al.  American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma , 2006, Annals of Surgical Oncology.

[46]  Claus Garbe,et al.  Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  C. Urso,et al.  Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation , 2004, Melanoma research.

[48]  M. Mottolese,et al.  Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. , 2007, Journal of experimental & clinical cancer research : CR.

[49]  C. Kaur,et al.  The correlation of regression in primary melanoma with sentinel lymph node status , 2007, Journal of Clinical Pathology.

[50]  D. Guerry,et al.  A population-based validation of the American Joint Committee on Cancer melanoma staging system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  PhD Zbigniew I. Nowecki MD,et al.  Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma , 2006, Annals of Surgical Oncology.

[52]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis , 2005, British Journal of Cancer.

[54]  M. Walker,et al.  Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. , 2003, Surgery.

[55]  D. McCready,et al.  Sentinel Lymph Node Biopsy for CutaneousMelanoma of the Head and Neck , 2005, Annals of Surgical Oncology.

[56]  R. Lyles,et al.  Sentinel Lymph Node Biopsy in the Management of Cutaneous Head and Neck Melanoma , 2005, Plastic and reconstructive surgery.

[57]  K. Drzewiecki,et al.  Sentinel node biopsy for melanoma: a study of 241 patients , 2004, Melanoma research.

[58]  D. Guerry,et al.  Is parathyroid carcinoma a lethal disease , 2004, Annals of Surgical Oncology.

[59]  P. Santini,et al.  Sentinel Node Biopsy in Clinical Stage 1 Melanoma: Rationale for Restaging and Follow-Up , 2000, Tumori.

[60]  S. Swetter,et al.  Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. , 2005, Archives of dermatology.

[61]  M. Berwick,et al.  The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma , 2005, Journal of cutaneous pathology.

[62]  D. Elder,et al.  Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Elashoff,et al.  Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: Therapeutic Utility and Implications of Nodal Microanatomy and Molecular Staging for Improving the Accuracy of Detection of Nodal Micrometastases , 2003, Annals of surgery.

[64]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[65]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[66]  P. Diest,et al.  Reliability of the Sentinel Node Procedure in Melanoma Patients: Analysis of Failures After Long-Term Follow-Up , 2000, Annals of Surgical Oncology.

[67]  K. Slim,et al.  Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument , 2003, ANZ journal of surgery.

[68]  M. Nosrati,et al.  Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.